Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Medicine Matters Home › Article of the Week › Page 9

Article of the Week

Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide

ARTICLE: Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide AUTHORS: Stefanie Krug, Manish Gupta, Pankaj Kumar, Laine Feller, Elizabeth A Ihms, Bong Gu Kang, Geetha Srikrishna, Ted… Read More »Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide

Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes

ARTICLE: Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes AUTHORS: Mandar Sudhir Paradkar, Neeta Nitin Pradhan, Subramanyam Balaji, Sanjay Narayan Gaikwad, Amol Chavan, Sujata Nagnath Dharmashale, Tushar Sahasrabudhe, Rahul Lokhande, Sona Anil Deshmukh, Madhusudan… Read More »Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes

Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors

ARTICLE: Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors AUTHORS: Sara Belga, Sarah Hussain, Robin K Avery, Zeba Nauroz, Christine M Durand, Elizabeth… Read More »Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors

Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection

ARTICLE: Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection AUTHORS: Nicole Frumento, Ariadne Sinnis-Bourozikas, Harry T… Read More »Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

ARTICLE: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) AUTHORS: Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric… Read More »Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones

ARTICLE: Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones AUTHORS: Filippo Dragoni, Abena K Kwaa, Caroline C Traut, Rebecca T Veenhuis, Bezawit… Read More »Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones

MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survival

ARTICLE: MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survival AUTHORS: C Korin Bullen, Alok K Singh, Stefanie Krug, Shichun Lun, Preeti Thakur, Geetha Srikrishna, William… Read More »MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survival